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Preparation and investigation of mefenamic acid –  
polyethylene glycol – sucrose ester solid dispersions
Mefenamic acid (MA) is a widely used non-steroidal anti-
inflammatory (NSAID) drug. The adverse effects typical of 
NSAIDs are also present in the case of MA, partly due to its 
low water solubility. The aim of this study was to increase 
the water solubility of MA in order to influence its absorp-
tion and bioavailability. Solid dispersions of MA were pre-
pared by the melting method using polyethylene glycol 
6000 and different types (laurate, D-1216; palmitate, P-1670; 
stearate, S-1670) and amounts of sucrose esters as carriers. 
The X-ray diffraction results show that MA crystals were 
not present in the products. Dissolution tests carried out in 
artificial intestinal juice showed that the product contain-
ing 10 % D-1216 increased water solubility about 3 times. 
The apparent permeability coefficient of MA across human 
Caco-2 intestinal epithelial cell layers was high and, de-
spite the difference in solubility, there was no further in-
crease in drug penetration in the presence of the applied 
additives.
Keywords: mefenamic acid, sucrose esters, PEG 6000, solid 
dispersion, Caco-2 cells
Mefenamic acid [MA, 2-(2,3-dimethylphenyl)aminobenzoic acid], an anthranilic acid 
derivative, is a widely used non-steroidal anti-inflammatory (NSAID) drug (1).
Regarding the pharmacokinetics of the drug, MA is absorbed from the small intestine 
(2), its bioavailability is about 90 % but is influenced by the amount of water ingested with 
the drug in fasting subjects. The tmax is attained in 2–4 hours, and steady-state concentra-
tion is reached in 2–3 days (2, 3).
Like other NSAIDs, MA can cause serious gastrointestinal adverse effects (bleeding, 
ulceration) due to its mechanism of action (4) and acting as an irritant of the gastrointesti-
nal mucosa (5).
MA belongs to class II of the biopharmaceutical classification system (BCS) – drugs 
with low solubility and high permeability; therefore, its oral bioavailability is determined 
by its dissolution rate in the gastrointestinal fluid and, consequently, it has variable absorp-
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tion (6, 7). In the literature, there are different methods to enhance MA solubility and dis-
solution rate. The most commonly used techniques are the formation of inclusion com-
plexes with several cyclodextrin derivatives (8–10) and preparation of solid dispersions 
(SD) with water soluble polymers (polyvinylpyrrolidone, PVP, or polyethylene glycol, PEG) 
(11) in binary and ternary systems with a disintegrant and Polysorbate 20, respectively (12). 
Solubility increase was achieved in both cases according to literature data, but there is no 
information regarding the effect of auxiliary substances on permeability. Auxiliary sub-
stances may negatively affect the permeability (13). The presence of hydroxy-propyl-b-
cyclodextrin decreased the permeability of dexamethasone in a Caco-2 cell model and in 
the in situ single-pass rat intestinal perfusion model (14) while Polysorbate 80 decreased 
permeability of progesterone across an artificial dimethicone membrane (15). Polymers 
such as PEG 400 are also able to reduce the permeability of lipophilic drugs (16). PEG with 
higher molecular mass increases the permeability coefficient (Papp) of indomethacin (17). 
The permeability-increasing effect of sucrose esters (SE) on Caco-2 cells was also demon-
strated (18).
The aim of our work was to increase the water solubility of MA in order to reduce its 
gastrointestinal adverse effects (19) and the variability of absorption. Modification of the 
permeability of MA in different solid dispersions was also evaluated (solubility-permea-
bility interplay). Ternary products were prepared with PEG 6000 and sucrose esters as 
carriers. Sucrose esters were chosen as ternary components because they can act as pene-
tration enhancers along with their solubility increasing property. Sucrose esters are non- 
-ionic surfactants (20, 21) and, due to their thermal behaviour (low melting point), can be 
used in preparation of solid dispersions made by the melting technique (21, 22). In this 
paper, beside the product preparation method, the solubility and permeability influencing 
properties of the obtained solid dispersions are presented.
EXPERIMENTAL
Materials
Mefenamic acid and all reagents were purchased from Sigma-Aldrich, Hungary, un-
less otherwise indicated. Laurate sucrose ester (D-1216, sucrose laurate) was of pharmaceu-
tical grade, palmitate (P-1670, sucrose palmitate) and stearate (S-1670, sucrose stearate) su-
crose esters were of analytical grade (Mitsubishi Kagaku Foods Co., Japan). PEG 6000 was 
supplied by Merck, Germany. All other reagents and solvents were of analytical grade.
Product preparation
Ternary products composed of MA, PEG 6000 and SE were prepared by the melting 
method. The SEs were dissolved (D1216) or suspended (P1670 and S1670) in the melted PEG 
6000 (80 °C). The temperature was increased to 110 °C, then the accurately weighed MA 
powder was added to the blend to dissolve under mixing for 20 minutes. The obtained 
mixtures were poured onto a cooled metal plate in a thin layer to cool quickly. The tem-
perature of the cooled plate was contolled by a JULABO cryothermostate model F32 (JU-
LABO model-F32, Labortechnik GmbH, Germany). The mixtures were kept at –20 °C for 
24 hours, then scraped off, pulverized in a mortar and passed through a 100-mm sieve. The 
products were stored at room temperature until analysis. The composition of the products 
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Table I. Composition o f the studied products
MA (%) SE (%) PEG (%) Product code
10
D-1216
  5 85 D5
10 80 D10
P-1670
  5 85 P5
10 80 P10
S-1670
  5 85 S5
10 80 S10
10 –   0 90 PEG
Characterization of solid dispersions
X-ray diffraction analysis. – X-ray diffraction (XRPD) analyses were conducted using a 
Rigaku MiniFlexTM II X-Ray diffractometer (Rigaku Co., Japan), where the tube anode was 
Cu with Kα = 1.5405 Ǻ. The data was collected using 30-kV tube voltage and 15-mA tube 
current in step scan mode (4 ° min–1). The instrument was calibrated using silicon.
In vitro dissolution studies and kinetic calculations. – Dissolution studies were performed 
in artificial gastric fluid (AGF, pH 1.2) and artificial intestinal fluid (AIF, pH 6.8) without 
enzymes, using the rotating paddle method according to Eur. Ph. – Pharma Test PTW-II, 
Germany (23), adapted to 100-mL dissolution medium. Amounts of samples equivalent to 
30 mg MA were introduced into hydroxypropyl methylcellulose capsules and immersed 
into the dissolution medium at a rotation speed of 100 rpm and temperature of 37 °C. Aliq-
uots of 50 mL were collected periodically and replaced with fresh dissolution medium. 
After filtration the concentration of MA was determined spectrophotometrically (ATI UNI-
CAM UV-VIS, spectrophotometer, USA) at 352 nm (AGF) and 288 nm (AIF). Measurements 
were performed in triplicate. Dissolution tests were conducted under non-sink conditions 
in order to evaluate the differences between the formulations. The mechanism of drug re-
lease was evaluated by different mathematical models offered by the DDSolver software 
(24). The best fit was chosen based on the adjusted coefficient of determination (R2adj) (25).
Cell culture, viability and permeability assays
The cell culture conditions and the methods for toxicity and permeability measure-
ments in the case of MA and its products were described by our group previously (26). 
Briefly, for the cytotoxicity assays, Caco-2 human intestinal epithelial cells were cultured 
in 96-well plates in Dulbecco’s modified Eagle’s medium without phenol red containing 
10 % fetal bovine serum (Gibco, Invitrogen, USA). During the treatment period, the plates 
were placed on a horizontal shaker at 100 rpm. Tested formulations contained 1, 10, 30, 100, 
300, 1000, 3000 mg mL–1 MA as the final concentration. Cytotoxicity was evaluated by: (i) 
measuring the lactate dehydrogenase (LDH) enzyme activity from culture supernatant 
is presented in Table I. All products contained 10 % of MA, 5 % or 10 % of sucrose ester 
(D1216, P1670 and S167, shortened as D, P and S, respectively) and 85 or 80 % of PEG 6000.
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using a LDH detection kit (Roche, Switzerland), (ii) testing cell metabolic activity by meas-
uring MTT dye [3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyltetrazolium bromide] conversion, 
reflecting the number of viable cells. To study the permeability of MA in solid dispersions, 
human Caco-2 cells were cultured on Transwell filter inserts (polycarbonate membrane, 
0.4-mm pore size, 1.12 cm2 surface area, Corning Costar Co., USA) for 21 days. The tran-
sepithelial electrical resistance (TEER) of Caco-2 monolayers varied between 450 and 600 
W cm–2, indicating good barrier properties. The treatment solutions contained 3 or 100 mg 
mL–1 MA dissolved in Ringer-Hepes buffer and MA penetration across cell layers was 
determined in the apical (donor) to basal (acceptor) direction for 1 hour. The concentrations 
of MA were determined both in the basolateral and apical compartments using a Merck 
HPLC system (consisting of a quaternary pump L-7100, auto sampler L-7200, column ther-
mostat L-7360, DAD detector L-7455, interface L-7000, solvent degasser L-7612, HSM man-
ager software) (Merck, Germany). The analysis was carried out at ambient temperature 
using a Purospher RP C18e (5 mm, 250 x 4.6 mm, Merck) column. Determinations were 
performed by isocratic elution at a flow rate of 1.5 mL min–1. The mobile phase composition 
consisted of 55 % 20 mmol L–1 phosphate buffer (pH 6.5) and 45 % acetonitrile. Volumes of 
100 mL were injected using the loop method; the detection wavelength was set at 281 nm. 
Calculations were performed by measurement of peak areas.
The apparent permeability (Papp) was calculated using the formula:
 
where dQ/dt is the rate of drug permeation across the cells, c0 is the donor compartment 
concentration at time zero and A is the area of the cell monolayer (1.12 cm2).
All data presented are means ± standard deviations. The values were compared using 
ANOVA followed by Dunnet’s test using (GraphPad Prism 5.0 software, GraphPad Software 
Inc., USA). The changes were considered statistically significant at p < 0.05. All experiments 
were repeated at least two times, the number of parallel samples varied between 3 and 8.
RESULTS AND DISCUSSION
X-ray diffraction analysis
The XRPD patterns of the MA, P1670 and solid dispersions are represented in Fig. 1. 
MA exists in two polymorphic forms. Based on our previous DSC thermograms (9) and 
the XRPD peaks observed at 6.4, 16.0, 21.5 and 26.3° (2q) (27, 28), the form I polymorph of 
MA was identified. The sharp, narrow peaks observed in the case of MA indicate its crys-
talline status. The diffractograms of pure PEG 6000 and P1670 showed broad peaks at 19.2, 
23.3 and 21.36° (2q), respectively. The peaks related to MA were not present in the case of 
solid dispersions and the peaks of PEG 6000 are reduced and shifted to higher angles, in-
dicating the amorphous state of the drug. In the case of solid dispersions, the peaks of PEG 
6000 are predominantly present. Therefore, it can be confirmed that the active ingredient 
is predominantly molecularly dispersed in the carrier or amorphous. The relative degree 
of crystallinity (RDC) was calculated at 16.5° using the formula (29):
 
0cA
dt
dQ
Papp =
SD
MA
RI
RDC
RI
=
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where RISD is the peak height of the solid dispersion and RIMA is the peak height of MA at 
the same angle. The RDC for P10 was 0.012 and 0.014, for D5 suggesting that only partially 
crystallized MA molecules are present in the products.
Dissolution studies
MA, a drug with an acidic character, dissolves slightly in AGF, especially its form I 
polymorph (27); after 120 minutes only 0.6 % of MA was dissolved. In the case of ternary 
products the dissolution curves showed a peak after 15–30 minutes, indicating that super-
saturation occured only when chiefly molecularly dispersed form was present, followed 
by recrystallization of the drug, which entailed a decrease in the amount dissolved. The 
best results were obtained with the S5 product, where 3.1 % of MA was dissolved after 120 
min.
In AIF, 9 % of MA was dissolved after 120 minutes (concentration of 2.70 mg per 100 
mL–1 was achieved). The amount of dissolved drug increased about 3 times (28.6 %) 8.58 
mg in 100 mL–1) in the product containing 10 % D-1216 compared to pure MA. In the case 
of other studied products, the dissolution rate of MA proved to be lower. Solubility de-
creased in the following order: D10 > S10 > P10 > D5 > P5 >S5 > PEG. The dissolution profiles 
in AIF are represented in Fig. 2.
The mechanism of drug release is described by the Gompertz function:
 
where Fmax is maximum dissolution, a determines the undissolved portion at time t = 1 
(scale factor), and b is the dissolution rate per unit time (shape factor) (30). The coefficients 
of determination were above 0.95 in all cases.
The Gompertz model is typically used for comparing release profiles of drugs with 
good solubility and intermediate release rates. This model has a steep increase at the 
)log(
max
teeFF
βα −−
⋅=
Fig. 1. XRPD patterns of the studied products (MA – mefenamic acid, P1670, PEG 6000 and solid dis-
persions D5 and P10 see (Table I).
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Fig. 2. Dissolution profiles of MA alone and in solid dispersions in artificial intestinal fluid (mean ± 
SD, n = 3).
begin ning and converges slowly to the asymptotic maximal dissolution (27). In our case, 
after fast wetting of the matrix, a certain amount of MA dissolved fast; after that, the dis-
solution media became saturated in MA because of the non-sink conditions. Similarly to 
data shown in Fig. 2, D10 was the most efficient of the studied products in increasing the 
MA dissolution rate according to dissolution profile data (Table II) compared to the Gom-
pertz model.
Effects of mefenamic acid and formulations on the viability of Caco-2 cells
MA was not toxic in concentrations lower than 100 mg mL–1 in both assays (MTT dye 
conversion and LDH release assays) but caused cell death at concentration of 1 mg mL–1 
(Table III). Formulation containing only PEG 6000 did not change the toxicity pattern of the 
active ingredient. Among the formulations, those containing S-1670 (S5 and S10) showed 
the highest toxicity, which was increased ten times compared to MA and PEG. P-1670-
containing samples (P5 and P10) were less toxic than formulations with S-1670. The non-
toxic concentrations of P-1670 were three times higher than that for S-1670; however, the 
concentrations killing cells were the same for samples S5, S10, P5 and P10. The best formu-
lation was the D5 sample containing D-1216, where the non-toxic concentration was 100 mg 
mL–1 and the toxic one was 300 mg mL–1.
Effect of formulations on transepithelial electrical resistance in Caco-2 cells
Caco-2 cell layers were treated by dilution of the samples containing 3 mg mL–1 of MA. 
After 1-hour treatment, the resistance of cell monolayers did not change; it remained in the 
range of the original 450–600 W cm–2 values. No significant differences were found in the 
resistance of cell monolayers treated with the products.
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Permeability measurement across Caco-2 cells
The permeability coefficient of MA was 49 × 10–6 cm s–1, reflecting its high permeabil-
ity rate and lipophilic character (Fig. 3).
PEG 6000 and sucrose esters could not further increase the permeability of MA at the 
tested low concentration (3 mg mL–1), when the active ingredient was already completely 
solubilized (Fig. 4). The permeability coefficient of MA decreased statistically significantly 
in products D5 and P10 (p < 0.05), since the hydrophilic auxiliary substances reduced the 
permeability of MA. The analysis was repeated in the case of MA, D5, D10 and PEG prod-
ucts using 100 mg mL–1 MA in the donor compartment. Similarly to the first set of experi-
ments, D10 and PEG did not cause any significant change in the permeability of MA, while 
D5 drug penetration decreased significantly (p < 0.05).
Table II. Dissolution kinetics of solid dispersions in AIF
Product
Fmax ± SD
(mg per 100 mL–1)
a ± SD
(min–1)
b ± SD
(min–1)
R2
MA 11.17 ± 2.49   223.20 ± 203.28 3.48 ± 1.64 0.9660
PEG   27.06 ± 14.11     88.12 ± 139.25 1.91 ± 1.41 0.9775
D5 21.87 ± 3.49   21.95 ± 20.75 2.28 ± 0.74 0.9514
D10 106.29 ± 36.80   5.98 ± 0.44 0.75 ± 0.08 0.9907
P5  60.32 ± 70.14 11.89 ± 4.96 1.34 ± 0.64 0.9806
P10   89.72 ± 50.31   6.10 ± 0.59 0.82 ± 0.37 0.9884
S5   29.86 ± 30.62   48.47 ± 41.30 2.76 ± 1.85 0.9612
S10   60.55 ± 33.04   8.84 ± 3.67 1.17 ± 0.51 0.9839
Fmax – maximum dissolution; a – undissolved portion at time t = 1 (scale factor); b – dissolution rate per unit time 
(shape factor)
Table III. Toxic effects of MA and its products on Caco-2 human epithelial cells after 24 hours 
Sample
MTT dye conversiona LDH release
TC0
(mg mL–1)
TC100
(mg mL–1)
TC0
(mg mL–1)
TC100
(mg mL–1)
MA 100 1000 100 1000
PEG 100 1000 100 1000
D5 100   300 100   300
D10   30   300   30   300
P5   30   100   30   100
P10   30   100   10   100
S5   10   100   10   100
S10   10   100   10   100
a TC0 – the highest non-toxic concentration (no toxicity); TC100 – 100 % toxic concentration
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Fig. 3. Permeability of mefenamic acid measured on Caco-2 epithelial cell layers after 1-hour treat-
ments with different formulations (Papp – apparent permeability coefficient, * statistically significant 
differences between the MA and the formulations, p < 0.05).
Fig. 4. Relationship between MA solubility and Papp in the case of D-1216 containing products (D5 and 
D10) and the binary product (PEG) (the rate of change was calculated by dividing the solubility of the 
product by the solubility of MA and the Papp of the products by the Papp of the MA).
The relationship between MA solubility and permeability
The relationship between MA solubility and permeability and its products with 
D-1216 is shown in Fig. 4. The solubility rate increased in this order: MA-PEG < D5 < D10. 
The rate of change of Papp (at 3 mg mL–1 MA) did not correlate with the solubility increment; 
neither ascendant nor descendant tendencies could be observed. This can be explained by 
the high permeability of MA and by the difference in pH values applied in the AIF (pH 6.8) 
and permeability (pH 7.4) studies.
CONCLUSIONS
The importance of increasing the water solubility of drugs belonging to BCS II class 
is well known. In the case of MA, besides increasing the biopharmaceutical properties of 
the drug using hydrophilic auxiliary substances, the severe adverse effects can be also 
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reduced in such formulations. Water-solubility increasing auxiliary substances may mod-
ify the permeability of different APIs. In this work, different formulations of MA were 
tested and the relationship between solubility and permeability was evaluated. MA was 
embedded in the PEG 6000 polymer in the presence of sucrose ester surfactants. Based on 
the dissolution test results, confirmed by the Gompertz-function parameters, the best re-
sults were obtained in the case of the 10 % D-1216 – containing product. This product also 
proved to be one of the best formulations in the cellular toxicity test on Caco-2 cells. The 
dissolved amount of MA after 120 min increased only moderately, but after 30 minutes a 
significant rise in the solubility of MA can be observed. Therefore, under in vivo conditions 
the higher dissolved amount of MA – which is available for absorption – may increase the 
absorption rate of MA.
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